Monoclonal gammopathy and neuropathy

Current Opinion in Neurology

Volumn 20, Issue 5, 2007, Pages 536-541

  Lozeron, Pierre ^a   Adams, David ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Light chain amyloidosis, monoclonal gammopathy; Monoclonal gammopathy of undetermined significance; Neuropathy; POEMS

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CHLORAMBUCIL; FLUDARABINE; IMMUNOGLOBULIN M; MELPHALAN; MYELIN ASSOCIATED GLYCOPROTEIN; RITUXIMAB; THALIDOMIDE; VINCA ALKALOID;

AMYLOID NEUROPATHY; CLINICAL ASSESSMENT; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ELECTROPHYSIOLOGY; HEMATOLOGIC DISEASE; HUMAN; LIGHT CHAIN; MONITORING; MONOCLONAL IMMUNOGLOBULINEMIA; NERVE BIOPSY; NERVE FIBER; NEUROPATHY; OUTCOME ASSESSMENT; PARAPROTEINEMIA; PRACTICE GUIDELINE; REVIEW; SENSORY NEUROPATHY; TREATMENT PLANNING;

AMYLOIDOSIS; HUMANS; PARAPROTEINEMIAS; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; POEMS SYNDROME; WALDENSTROM MACROGLOBULINEMIA;

EID: 34648858607     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3282ef79e3     Document Type: Review

References (56)

1. Eurelings M, Lokhorst HM, Kalmijn S, et al. Malignant transformation in polyneuropathy associated with monoclonal gammopathy. Neurology 2005; 64:2079-2084.
2. European Federation of Neurological Societies/Peripheral Nerve Society. Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Periph Nerv Syst 2006; 11:9-19. This is a practical article with review of the most recent data for management and treatment of different subtypes of demyelinating NMG.
3. Dimopoulos MA, Moulopoulos LA, Datseris I, et al. Imaging of myeloma bone disease - implications for staging, prognosis and follow-up. Acta Oncol 2000; 39:823-827.
4. Ghanem N, Lohrmann C, Engelhardt M, et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 2006; 16:1005-1014. This report details the advantages of magnetic resonance imaging for the search of bone lesions.
5. Nobile-Orazio E, Barbieri S, Baldini L, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenic studies. Acta Neurol Scand 1992; 85:383-390.
6. Vrethem M, Cruz M, Wen-Xin H, et al. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci 1993; 114:193-199.
7. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362-1369. This article provides the most recent data about MGUS from a leader in the field.
8. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564-569.
9. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002; 20:1625-1634.
10. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106:812-817.
11. Keren DF, Raymond Alexanian R, Goeken JA, et al. Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies. Arch Pathol Lab Med 1999; 123:106-107.
12. Caudie C, Vial C, Petiot P, et al. Monoclonal IgM autoantibody activity vis-à-vis glycoconjugates of peripheral nerves: apropos of 112 cases. Ann Biol Clin (Paris) 2001; 59:567-577.
13. Steck AJ, Stalder AK, Renaud S. Antimyelin-associated glycoprotein neuropathy. Curr Opin Neurol 2006; 19:458-463. This is a recent review of anti-MAG neuropathy with a particular focus on pathophysiology.
14. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucoronyl paragloboside. Brain 1994; 117:941-947.
15. Trojaborg W, Hays AP, Van den Berg L, et al. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve 1995; 18:730-735.
16. Franssen H, Notermans NC. Length dependence in polyneuropathy associated with IgM gammopathy. Ann Neurol 2006; 59:365-371. This paper provides convincing evidence for a length-dependent involvement in a demyelinating neuropathy.
17. Lunn MPT, Nobile-Orazio E. Immunotherapy for IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2006; 2:CD002827. The study provides a consensus report for the management and treatment of anti-MAG neuropathy.
18. Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000; 123:710-717.
19. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003; 27:611-615.
20. Gironi M, Saresella M, Ceresa L, et al. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and antimag neuropathy after treatment with rituximab. Haematologica 2006; J91 (Suppl 6):ECR17. This is just one of the reports of the worsening of neuropathy following rituximab injection.
21. Broglio L, Lauria G. Worsening after rituximab treatment in antimag neuropathy. Muscle Nerve 2005; 32:378-379.
22. Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006; 66:742-744.
23. Eurelings M, Moons KGM, Notermans NC, et al. Neuropathy and IgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology 2001; 56:228-233.
24. Willison HJ, Yuki N. Peripheral neuropathies and antiglycolipid antibodies. Brain 2002; 125:2591-2625.
25. Di Troia A, Carpo M, Meucci N, et al. Clinical features and antineural reactivity in neuropathy associated with monoclonal IgG monoclonal gammopathy of undetermined significance. J Neurol Sci 1999; 164:64-71.
26. Nobile Orazio E, Castellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol 2002; 158:979-987.
27. Magy L, Chassande B, Maisonobe T, et al. Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. Eur J Neurol 2003; 10:677-685.
28. Allen D, Lunn MPT, Niermeijer J, Nobile-Orazio E. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev 2007; 1:CD005376. This is the most recent overview of what is known about treatment of IgG/IgA NMG.
29. Levine T, Pestronk A, Florence J, et al. Peripheral neuropathies in Waldenström's macroglobulinaemia. J Neurol Neurosurg Psychiatry 2006; 77:224-228. This report describes the symptoms and signs of peripheral neuropathy in a cohort of patients with Waldenström's macroglobulinaemia.
30. Dellagi K, Dupouey P, Brouet JC, et al. Waldenstrom's macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients. Blood 1983; 62:280-285.
31. Bajada S, Mastaglia FL, Fisher A. Amyloid neuropathy and tremor in Waldenstrom's macroglobulinemia. Arch Neurol 1980; 37:240-242.
32. Lamarca J, Casquero P, Pou A. Mononeuritis multiplex in Waldenstrom's macroglobulinemia. Ann Neurol 1987; 22:268-272.
33. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:116-120.
34. Dimopoulos MA, Merlini G, Leblond V, et al. How we treat Waldenstrom's macroglobulinemia. Haematologica 2005; 90:117-125.
35. Gertz MA, Fonseca R, Rajkumar SV. Waldenström's macroglobulinemia. Oncologist 2000; 5:63-67.
36. Denier C, Lozeron P, Adams D, et al. Multifocal neuropathy due to plasma cell infiltration of peripheral nerves in multiple myeloma. Neurology 2006; 66:917-918.
37. Bardwick PA, Zvaifler NJ, Gill GN, et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) 1980; 59:311-322.
38. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003; 101:2496-2506.
39. Kelly JJ Jr. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve 1983; 6:504-509.
40. Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 2005; 128:1911-1920.
41. Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 1984; 34:712-720.
42. Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome and a review of the literature. Blood 2004; 104:3400-3407.
43. Mineta M, Hatori M, Sano H, et al. Recurrent Crow-Fukase syndromeassociated with increased serum levels of vascular endothelial growth factor: a case report and review of the literature. Tohoku J Exp Med 2006; 210:269-277. This is an interesting report about a correlation between VEGF level and clinical course of POEMS syndrome.
44. Straume O, Bergheim J, Ernst P, et al. Bevacizumab therapy for POEMS syndrome. Blood 2006; 107:4972-4974.
45. Kanai K, Kuwabara S, Misawa S, Hattori T. Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Int Med 2007; 46:311-313.
46. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337:898-909.
47. Kelly JJ. Neurologic complications of primary systemic amyloidosis. Rev Neurol Dis 2006; 3:173-181. This paper provide recent data about amyloidosis.
48. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998; 104:232-237.
49. Comenzo RL. Amyloidosis. Curr Treat Options Oncol 2006; 7:225-236.
50. Nemni R, Sanvito L, Quattrini A, et al. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry 2003; 74:1267-1271.
51. Gemignani F, Brindani F, Alfieri S, et al. Clinical spectrum of cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 2005; 76:1410-1414.
52. Suzuki H, Takei T, Tsuji H, et al. Membranoproliferative glomerulonephritis and demyelinating neuropathy caused by type II mixed cryoglobulinemia associated with HCV infection. Intern Med 2000; 39:397-400.
53. Authier FJ, Bassez G, Payan C, et al. Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy. Neurology 2003; 60:808-812.
54. Boukhris S, Magy L, Senga-mokono U, et al. Polyneuropathy with demyelinating features in mixed cryoglobulinemia with hepatitis C virus infection. Eur J Neurol 2006; 13:937-941.
55. Ammendola A, Sampaolo S, Migliaresi S, et al. Autonomic neuropathy in mixed cryoglobulinemia. J Neurol 2007; 254:215-219.
56. Said G. Indications and usefulness of nerve biopsy. Arch Neurol 2002; 59:1532-1535.